On this page
Epidermolysis bullosa (junctional)
This condition results from pathogenic variants in genes encoding laminin proteins, which are essential for anchoring the upper skin layers to deeper structures. Blistering typically begins at birth or in early infancy, affecting skin and internal body surfaces.
Available at Jeen Health
Clinical tests that include this
Overview
Junctional epidermolysis bullosa (JEB) represents a group of rare genetic conditions characterised by extreme fragility of the skin and mucous membranes. The condition develops because structural proteins at the junction between the epidermis (outer skin layer) and dermis (deeper layer) fail to function properly, causing these layers to separate easily. Even minor friction or pressure can trigger painful blisters and erosions. The severity of JEB varies considerably, ranging from localised blistering to widespread involvement that can be life-threatening in infancy.
This condition typically manifests at birth or within the first few months of life. Affected individuals experience recurrent blistering that heals slowly and may leave scarring or changes in skin pigmentation. The exact prevalence is not well established, but JEB is considered rare, affecting fewer than 1 in 100,000 births. Because the proteins involved are present in various tissues throughout the body, blistering is not limited to external skin and can affect the mouth, oesophagus, airways, and other internal surfaces.
JEB follows an autosomal recessive inheritance pattern, meaning both parents typically carry one non-working copy of the causative gene without showing symptoms themselves. When both parents are carriers, each pregnancy has a 25% chance of producing an affected child. Genetic testing and specialist dermatology care are essential for accurate diagnosis and ongoing management within the NHS.
Symptoms & clinical features
The hallmark feature of junctional epidermolysis bullosa is the development of fluid-filled blisters and raw, eroded areas on the skin following minimal trauma or friction [PMID:29352738]. These blistering episodes often begin in the newborn period, affecting areas subject to pressure or rubbing such as the hands, feet, elbows, and nappy area. When skin layers pull apart at their connecting boundary, blisters appear and may heal gradually, sometimes leaving permanent marks. In severe forms, widespread blistering may cover large body surface areas, leading to fluid loss, infection risk, and nutritional challenges.
Beyond the skin, JEB commonly affects mucous membranes. Blistering inside the mouth can make eating and swallowing difficult, whilst involvement of the oesophagus may cause narrowing (strictures) over time, further complicating nutrition [PMID:31811904]. The scalp is frequently affected, and repeated blistering can lead to scarring hair loss (alopecia). Dental enamel abnormalities are also characteristic, with teeth appearing discoloured, pitted, or prone to decay due to defects in enamel formation. Some individuals develop hoarseness or breathing difficulties if blistering affects the larynx or airways. Nail dystrophy, with thickened or absent nails, is another common feature. The chronic nature of these symptoms significantly impacts quality of life and requires coordinated multidisciplinary care.
Video: Genetics 101
Affected organs
Whilst junctional epidermolysis bullosa primarily manifests as a skin condition, the proteins involved are expressed in epithelial tissues throughout the body, meaning multiple organ systems can be affected. The skin itself bears the most visible burden, with the epidermis separating from the dermis at sites of mechanical stress. The gastrointestinal tract is particularly vulnerable, with the mouth, oesophagus, and occasionally the stomach and intestines developing blistering and erosions that can interfere with nutrition and growth [PMID:28520103].
The respiratory tract may also be involved, particularly the larynx and upper airways, where blistering can cause hoarseness, breathing difficulties, or airway narrowing. The eyes can be affected, with recurrent erosions of the cornea or conjunctiva leading to scarring and potential vision problems. The urinary tract is less commonly involved but can experience blistering, particularly around the urethra. Hair follicles and tooth enamel formation are disrupted due to the structural defects in basement membrane proteins, resulting in scarring alopecia and dental abnormalities. The cumulative effect of involvement across these systems requires multidisciplinary NHS specialist input to manage complications and optimise quality of life.
Risks & severity
The severity of junctional epidermolysis bullosa exists on a spectrum. The most severe forms, historically termed JEB-Herlitz or JEB-generalisata gravis, present with extensive blistering from birth, significant mucosal involvement, and profound complications including failure to thrive and sepsis [PMID:29352738]. Infants with these severe variants face high mortality in the first year of life due to overwhelming infection, respiratory complications, or malnutrition. Survival beyond infancy is possible with intensive supportive care, but ongoing challenges with wound healing, nutrition, and infection remain.
Milder forms of JEB, sometimes called non-Herlitz subtypes, have a better long-term outlook. Blistering may be more localised, mucosal involvement less severe, and individuals can survive into adulthood with appropriate management. However, even milder variants cause chronic pain, restricted mobility, and complications such as oesophageal strictures. Dental problems are common across all severities. Long-term risks include chronic wounds, joint contractures from repeated blistering, and in some cases, an increased risk of skin cancer, though this is less pronounced than in dystrophic forms of epidermolysis bullosa. Early diagnosis and connection with specialist NHS services significantly influence outcomes.
Genetic causes
Junctional epidermolysis bullosa results from pathogenic variants in genes encoding laminin proteins, which are critical components of the basement membrane zone connecting the epidermis to the dermis. The three genes most commonly implicated are LAMA3, LAMB3, and LAMC2, which encode the alpha-3, beta-3, and gamma-2 subunits of laminin-332 (previously known as laminin-5) [PMID:31811904]. Inside the tissue connecting layer, these protein pieces join together and anchor skin cells to the structural framework beneath through specialised attachment points.
Pathogenic changes in these genes compromise the assembly or stability of laminin-332, weakening the adhesion between skin layers. Without effective anchoring, mechanical forces easily cause the epidermis to detach from the dermis, producing blisters precisely at the junction between these two zones. The degree of functional impairment varies: variants that completely prevent protein production generally produce the most severe clinical presentations, whilst those permitting some residual activity may lead to milder phenotypes [PMID:28520103]. Genetic testing identifies the specific causative variants, information that helps predict disease trajectory and supports informed family planning conversations.
- LAMA3 laminin subunit alpha 3The LAMA3 gene provides instructions for a key component of laminin 332, a protein vital for skin structure and integrity, and is associated with certain inherited skin disorders.
- LAMB3 laminin subunit beta 3The LAMB3 gene provides instructions for the beta-3 subunit of laminin 332, a critical protein for maintaining the structural integrity and adhesion of skin and other tissues.
- LAMC2 laminin subunit gamma 2The LAMC2 gene provides instructions for making a critical component of laminin 332, a protein essential for the structural integrity and adhesion of skin and other tissues.
Inheritance pattern
Junctional epidermolysis bullosa is inherited in an autosomal recessive pattern. This means an affected individual has inherited two non-functioning copies of one of the causative genes, typically one from each parent. Parents who carry a single pathogenic variant are usually clinically unaffected because they still have one working copy of the gene producing sufficient functional protein. When both parents are carriers, each pregnancy has a 25% chance of producing an affected child, a 50% chance of producing a carrier child, and a 25% chance of producing a child with two working copies.
If an individual has junctional epidermolysis bullosa, their siblings have a 25% risk of also being affected if both parents are carriers. Extended family members may also be carriers, particularly in communities where consanguinity (marriage between relatives) is more common, as this increases the likelihood that both parents carry the same rare variant. Genetic counselling is available through NHS clinical genetics services to help families understand recurrence risks, discuss reproductive options such as preimplantation genetic testing or prenatal diagnosis, and make informed decisions. Carrier testing for at-risk relatives can clarify their status before they have children of their own.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of junctional epidermolysis bullosa typically begins with clinical recognition of characteristic blistering patterns in infancy or early childhood. A dermatologist with expertise in genetic skin conditions will perform a skin biopsy from the edge of a fresh blister. Specialised laboratory techniques, including immunofluorescence mapping and transmission electron microscopy, examine where the skin layers are separating and which proteins are absent or abnormal [PMID:29352738]. In JEB, the split occurs within the lamina lucida region of the basement membrane zone, distinguishing it from other epidermolysis bullosa subtypes.
Genetic testing confirms the diagnosis by identifying pathogenic variants in LAMA3, LAMB3, or LAMC2. This is typically arranged through NHS clinical genetics services following referral from dermatology or paediatrics. Testing may be conducted as part of the NHS Genomic Medicine Service using gene panels that cover epidermolysis bullosa-related genes. Relevant PanelApp codes include the Epidermolysis bullosa panel (R82). Confirming the genetic cause allows accurate genetic counselling for families, helps predict disease severity, and enables prenatal or preimplantation testing for future pregnancies if desired. Early diagnosis connects families with specialist multidisciplinary teams experienced in managing this complex condition.
Management & lifestyle
Management of junctional epidermolysis bullosa focuses on preventing blistering, treating wounds, managing complications, and supporting quality of life. Care is coordinated through specialist NHS centres with multidisciplinary teams including dermatology, nursing, dietetics, dentistry, and physiotherapy. Meticulous wound care is essential, using non-adherent dressings that minimise trauma during changes. Infection surveillance and prompt treatment with antibiotics when needed helps prevent sepsis. Nutritional support is often required, particularly when oesophageal involvement impairs eating; some individuals need gastrostomy feeding tubes to maintain adequate growth.
Regular monitoring for complications includes dental surveillance to manage enamel defects and decay, assessment for oesophageal strictures requiring dilatation, and blood count monitoring. Physiotherapy helps maintain joint mobility and prevent contractures. Pain management is important, as chronic wounds cause significant discomfort. There is no cure for JEB, and gene therapy or protein replacement approaches remain experimental. Families are supported through NHS specialist epidermolysis bullosa services and patient organisations such as DEBRA UK, which provides practical information and psychosocial support.
UK care pathway
In the UK, individuals with suspected or confirmed junctional epidermolysis bullosa are referred to specialist dermatology services, often through paediatrics if diagnosed in infancy. NHS England commissions specialist epidermolysis bullosa services at designated centres that provide expert multidisciplinary care. Genetic testing is accessed through NHS clinical genetics services via the Genomic Medicine Service, using the Epidermolysis bullosa gene panel (PanelApp R82 code). Referral to clinical genetics also enables families to meet with genetic counsellors who explain inheritance patterns, recurrence risks, and reproductive options.
Ongoing care involves regular review at the specialist centre, with community support from dermatology nursing teams who provide wound care training and supplies. Coordination between hospital and community services ensures families have access to appropriate dressings, nutritional support, and allied health input. Transition planning for young people moving from paediatric to adult services is an important consideration. Families are encouraged to engage with patient support organisations and may be offered psychological support to help cope with the demands of managing a chronic, painful condition.
Frequently asked questions
Will my child's blistering improve as they get older?
The natural course varies depending on disease severity. Some individuals with milder forms may experience slightly less frequent blistering with age, but junctional epidermolysis bullosa remains a lifelong condition requiring ongoing wound care and monitoring. Specialist teams can help optimise management strategies as your child grows.
Can junctional epidermolysis bullosa be cured?
Currently there is no cure for junctional epidermolysis bullosa. Management focuses on preventing blistering, treating wounds, and managing complications. Research into gene therapy and other novel treatments is ongoing, but these approaches remain experimental and are not yet available as standard NHS treatment.
What is the risk of having another affected child?
If both parents are carriers of a pathogenic variant in the same laminin gene, the recurrence risk is 25% for each pregnancy. Genetic counselling through NHS clinical genetics services can clarify your family's specific situation and discuss options such as prenatal testing or preimplantation genetic testing if you wish to consider them.
How can I prevent my child's skin from blistering?
Minimising friction and trauma is key. This includes using soft clothing without rough seams, lifting rather than pulling during handling, avoiding adhesive products directly on skin, and using specialised non-adherent dressings. Your specialist nursing team will provide detailed guidance tailored to your child's needs and teach practical techniques for daily care.
Are there any dietary changes that might help?
Whilst no specific diet treats junctional epidermolysis bullosa, maintaining good nutrition is essential for wound healing and overall health. A dietitian can advise on soft foods if mouth or oesophageal blistering makes eating difficult, and may recommend supplements or alternative feeding routes if nutritional intake becomes inadequate.
References
- Hon KL, Chu S, Leung AKC. Epidermolysis Bullosa: Pediatric Perspectives. Current pediatric reviews. 2022. PMID: 34036913
- Pai S, Marinkovich MP. Epidermolysis bullosa: new and emerging trends. American journal of clinical dermatology. 2002. PMID: 12113646
- Thien CI, Bessa VR, Miotto IZ. Hereditary epidermolysis bullosa: clinical-epidemiological profile of 278 patients at a tertiary hospital in São Paulo, Brazil. Anais brasileiros de dermatologia. 2024. PMID: 38403552
- Sánchez-Jimeno C, Escámez MJ, Ayuso C. Genetic diagnosis of epidermolysis bullosa: recommendations from an expert Spanish research group. Actas dermo-sifiliograficas. 2018. PMID: 29180129
- Du R, Dinckan N, Song X. Identification of likely pathogenic and known variants in TSPEAR, LAMB3, BCOR, and WNT10A in four Turkish families with tooth agenesis. Human genetics. 2018. PMID: 30046887
- Raviv Sasportas E, Carmon D, Avizemer H. Diamond Burr Keratectomy for Bilateral Recurrent Corneal Erosion Syndrome in Epidermolysis Bullosa: A Case Report. Ocular immunology and inflammation. 2026. PMID: 42289356